Early-stage biotech companies can make some big promises to their investors — lofty claims that they’re creating the first drug to treat a disease or first to use a new kind of biology or chemistry. And in return for those promises, investors hand over millions of dollars.

But early-stage companies are private. For outsiders, sporadic press releases contain clues about where a company’s headed — but asking the company’s leadership and staff is the only real way to find out exactly what’s going on.

Continue to STAT Plus to read the full story…

Source link